Hansen T, Ambye L, Grarup N, Hansen L, Echwald S M, Ferrer J, Pedersen O
Steno Diabetes Center, Gentofte, Denmark.
Diabetologia. 2001 Oct;44(10):1330-4. doi: 10.1007/s001250100651.
AIMS/HYPOTHESIS: We aimed to examine the promoter of SUR1 for genetic variation and to determine if variants were associated with Type II (non-insulin-dependent) diabetes mellitus or measures of beta-cell function.
We examined 465 bp upstream of the ATG site in 46 Type II diabetic patients and 15 glucose tolerant control subjects by SSCP-heteroduplex analysis.
We identified an a --> t substitution 437 bp upstream of the ATG site. The allelic frequency was similar in 455 unrelated Type II diabetic patients and in 203 glucose tolerant control subjects matched for age (0.036, [95 % CI 0.019-0.053] vs 0.034 [95 % CI 0.009-0.059]; p = 0.92). Among the glucose tolerant subjects there were no differences between non-carriers (n = 189) and carriers (n = 14) of the variant in fasting values or 30 min values of plasma glucose and serum insulin during an oral glucose tolerance test. In a study of 233 glucose tolerant offspring of and spouses to Danish Caucasian Type II diabetic patients, non-carriers (n = 193) and carriers (n = 37) of the -437 a/t polymorphism did not differ in glucose or tolbutamide stimulated insulin response during an intravenous glucose tolerance test with intravenous tolbutamide injection [AUCs-insulin (0-8) min, 2290 +/- 1660 vs 2308 +/- 1935 pmol/l x min and AUCs-insulin(20-30 min), 3113 +/- 2033 vs. 3393 +/- 2830 pmol/l x min, respectively].
CONCLUSION/INTERPRETATION: We have identified a novel a/t polymorphism of the SUR1 gene promoter which is not associated with Type II diabetes mellitus or measures of beta-cell function. Previous reported non-functional variants of SUR1 associated with Type II diabetes mellitus still need to be accounted for.
目的/假设:我们旨在研究磺脲类药物受体1(SUR1)启动子的基因变异情况,并确定这些变异是否与II型(非胰岛素依赖型)糖尿病或β细胞功能指标相关。
我们通过单链构象多态性-异源双链分析,检测了46例II型糖尿病患者和15例糖耐量正常对照者ATG位点上游465 bp的区域。
我们在ATG位点上游437 bp处发现了一个a→t的替换。在455例无亲缘关系的II型糖尿病患者和203例年龄匹配的糖耐量正常对照者中,该等位基因频率相似(0.036,[95%可信区间0.019 - 0.053] 对比 0.034 [95%可信区间0.009 - 0.059];p = 0.92)。在糖耐量正常的受试者中,该变异的非携带者(n = 189)和携带者(n = 14)在口服葡萄糖耐量试验期间的空腹血糖值、30分钟血糖值和血清胰岛素值方面没有差异。在一项对233例丹麦白种人II型糖尿病患者的糖耐量正常后代及配偶的研究中,-437 a/t多态性的非携带者(n = 193)和携带者(n = 37)在静脉注射葡萄糖耐量试验(静脉注射甲苯磺丁脲)期间,葡萄糖或甲苯磺丁脲刺激后的胰岛素反应无差异 [胰岛素曲线下面积(0 - 8)分钟,分别为2290±1660对比2308±1935 pmol/l×分钟;胰岛素曲线下面积(20 - 30分钟),分别为3113±2033对比3393±2830 pmol/l×分钟]。
结论/解读:我们发现了SUR1基因启动子一种新的a/t多态性,它与II型糖尿病或β细胞功能指标无关。先前报道的与II型糖尿病相关的SUR1无功能变异仍需进一步研究。